Beyond Major Pathologic Response in Lung Cancer: Biomarkers Predict Outcomes
Related Experiment Video
Updated: Sep 20, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Victoria E Wang1, Natalie M Ward1, Johannes R Kratz1
1University of California, San Francisco San Francisco, CA United States.
Abstract:
Neoadjuvant chemoimmunotherapy improves outcomes in resectable non-small cell lung cancer, yet pathologic response incompletely predicts durability of benefit. Spatial profiling using resected tumors and lymph nodes revealed distinct immune subtypes and identified a gene signature associated with improved outcomes, providing a framework for biomarker-guided treatment selection and prospective validation.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021